**Title: Identifying a core outcome set for pulmonary sarcoidosis research – the Foundation for Sarcoidosis Research – Sarcoidosis Clinical OUtcomes Taskforce (SCOUT)**

**Running Title: A core outcome set for pulmonary sarcoidosis research**

**Key words: Pulmonary sarcoidosis, Core outcome set, Outcomes**

**Abstract**

**Background**

Pulmonary sarcoidosis is a rare granulomatous disease of unknown aetiology. Heterogeneity in the outcomes measured in trials of treatment for pulmonary sarcoidosis has impacted on the ability to systematically compare findings, contributing to research inefficiency. The FSR-SCOUT study has aimed to address this heterogeneity by developing a core outcome set that represents a patient and health professional consensus on the most important outcomes to measure in future research for the treatment of pulmonary sarcoidosis.

**Research design and methods**

A systematic review of trial registries, narrative synthesis of published qualitative literature on the patient experience and results of a patient survey contributed to the development of a comprehensive list of outcomes that were rated in a two round online Delphi survey. The Delphi survey was completed by patients/carers and health professionals and the results discussed and ratified at an online consensus meeting.

**Results**

259 patients/carers and 51 health professionals completed both rounds of the Delphi survey. A pre-agreed definition of consensus was applied and the results discussed at an online consensus meeting attended by 17 patients and 7 health professionals). Fifteen outcomes, across five domains (physiological/clinical, treatment, resource use, quality of life, and death), reached the definition of consensus and were included in the core outcome set.

**Conclusions**

The core outcome set represents a patient and health professional consensus on the most important outcomes for pulmonary sarcoidosis research. The use of the core outcome set in future trials, and efforts to validate its components, will enhance the relevance of trials to stakeholders and will increase the opportunity for the research to contribute to evidence synthesis.

**Background:**

Sarcoidosis is a systemic granulomatous disease of unknown aetiology. Sarcoidosis can affect any organ but most commonly affects the lungs with lung involvement observed in more than 90% of sarcoidosis patients [1-3]. Pulmonary sarcoidosis may cause significant pulmonary symptoms, pulmonary dysfunction, and life-threatening complications such as pulmonary hypertension and end-stage pulmonary disease. The management of pulmonary sarcoidosis is aimed at preventing/controlling organ damage, relieving symptoms, and improving the patient’s quality of life.

A systematic review of outcomes measured in clinical trials evaluating treatments for pulmonary sarcoidosis has identified heterogeneity in the outcomes measured [4] . This review also noted differences in the outcomes measured and reported in phase2/3/4 clinical trials and studies that report the patient experience suggesting that outcomes that are most important/relevant to patients may not have always be considered in clinical trials. This heterogeneity in the choice of outcomes and the methods of assessment has impacted on the ability to combine evidence in meta-analyses [5, 6]. One way to address this heterogeneity and subsequent research waste is to use a core outcome set (COS), defined as “the minimum [set of outcomes] that should be measured and reported in all clinical trials of a specific condition” [7].

Whilst some work to harmonise outcomes in the field of pulmonary sarcoidosis has already been undertaken [8, 9] there have been limitations to the methodology used, for example, a limited range of stakeholders or the rating of a short list of pre-selected outcomes only. Consequently, a need to develop a set of core outcomes, developed in-line with the COS-STAD guidelines[10], that reflected the opinions of health professionals, patients and researchers was identified.

The aim of the Sarcoidosis Core Outcomes Taskforce (SCOUT) study was to develop a COS for use in clinical trials of any intervention for the treatment of pulmonary sarcoidosis that includes input from health professionals, patients and researchers in the field. Recognizing that many of the outcomes that have been used are not validated, the long-term goal of this project is to prioritize outcomes that can be subjected to future research for validation.

**Methods:**

The development of the COS involved three stages: the generation of a long list of outcomes for use in an online Delphi survey, a two round online Delphi survey with key stakeholders and an online consensus meeting to discuss the results of the survey and agree the COS (figure 1).

The methods for each step are described briefly below, a study protocol and systematic review describing methods have been published elsewhere [11, 12].

**Outcome list generation**

The outcome list for use in the online Delphi survey was generated using three sources: registered clinical trials for interventions to treat pulmonary sarcoidosis, published qualitative literature relating to the patient experience and a written patient questionnaire completed by a patient advisory group. The search strategies used for registered trials and qualitative literature have been published elsewhere [12]. The patient questionnaire is provided in supplementary file 1. Outcomes were extracted verbatim from each source and then grouped using a standardised outcome name. Outcomes were also categorised using the taxonomy of Dodd et al [13]. Outcomes relating to a diagnostic procedure, specific to pulmonary hypertension or considered by the SSC to be unrelated to pulmonary sarcoidosis were not included. The resulting list of outcomes was reviewed by the SSC and plain language descriptions developed for each outcome.

 **Delphi survey**

The final list of outcomes was used to populate an online Delphi survey delivered using the DelphiManager platform [14]. Delphi participants were invited from three key stakeholder groups: health professionals with experience of treating sarcoidosis, researchers in the field, and patients with pulmonary sarcoidosis and their carers. No restrictions were placed on patients in terms of time with pulmonary sarcoidosis, current or previous treatment or co-morbidities. However, patients with co-morbidities were advised to consider only their pulmonary sarcoidosis when responding to the Delphi survey. Invitations to take part were distributed via the Foundation for Sarcoidosis Research using established mailing lists of patients and health professionals, the study invitation was also distributed to the WASOG (World Association of Sarcoidosis and other Granulomatous Disorders), AASOG (Americas Association of Sarcoidosis and Other Granulomatous Disorders), and St. Antonius international network of expertise sarcoidosis centre. As part of the registration for the online Delphi, patient participants self-selected as having experience of living with pulmonary sarcoidosis, no further detail was collected on the nature or duration of symptoms, or the presence of co-morbidities.

The Delphi process comprised two rounds, round 1 (R1) and round 2 (R2). In each round the list of outcomes was presented and asked to rate each outcome, on how important it was to include it in the COS, using a nine point Likert scale presented in the format 1 to 9, with 1 to 3 labelled ‘not important’, 4 to 6 labelled ‘important but not critical’ and 7 to 9 labelled ‘critically important’[15]. At the end of R1 participants were able to add any additional outcomes that they felt were missing from the list. Outcomes added in R1 were reviewed by the SSC and any suggestions representing a new outcome were added to the list to be rated in R2. Outcomes were not removed from the list between R1 and R2.

During R2, participants were shown their rating from R1 along with a histogram of the distribution of scores for each stakeholder group for each outcome. Participants were asked to consider this information before rating the outcome again using the same 1-9 Likert scale.

For the purpose of the histograms two stakeholder groups were shown “health professionals” and “patients” with “researchers” included in the “health professionals group”.

**Consensus meeting**

An online consensus meeting was held using the Zoom platform. The meeting was structured using the consensus matrix of round 2 results (supplementary file 2) to identify outcomes that had met the pre-defined definition of consensus “in” or consensus “out” (table 1) and outcomes where there was disagreement between stakeholder groups. The criteria for the inclusion of an outcome was 70% or more in each stakeholder group rating an outcome 7-9 and less than 15%, in each group, rating 1-3. This criteria was chosen based on cut off values used in previous core outcome sets. 70% represents a balance between a less stringent cut off e.g. 50% that could result in COS with an unwieldy number of outcomes, and a more stringent cut off e.g. 90% that may exclude some important outcomes. Participants who had completed both R1 and R2 of the Delphi survey were invited to attend the consensus meeting and, if interested in attending, were asked to confirm this at the end of R2.We anticipated a maximum of 30-40 consensus meeting participants, if the number of people expressing an interest in attending exceeded this, places would be offered to ensure representation of each stakeholder group and the roles within these i.e. patient or carer, clinical role, research experience etc. Prior to the meeting participants received a summary of what to expect on the day, a summary of outcomes that would be discussed at the meeting that included the Delphi ratings of each stakeholder group, and a copy of their own ratings from the online Delphi. The meeting was chaired by an independent non-clinical researcher with expertise in COS development. Outcomes that had reached the definition of “consensus in” or “consensus out” were sent to participants prior to the meeting and not discussed. Outcomes that had had been rated 7-9 by 70% or more of participants in one stakeholder group were discussed at the meeting. Outcomes where neither group rated the outcome as “consensus in” were not discussed. For the purpose of the consensus meeting, outcomes prioritised for discussion were grouped into four domains; physiological/clinical, health and quality of life, life impact and treatment. All outcomes for discussion in a particular domain were presented, alongside outcomes in the same domain that had met the definition of “consensus in” and would be included in the COS. Meeting participants were invited to provide comments for inclusion of outcomes followed by comments against. After discussion of outcomes in that domain participants rated each outcome, that had been discussed, on how important it was to include it in the COS using the 1-9 scale (1 not that important – 9 critically important). Patients and health professionals voted separately and anonymously, using separate polls delivered using the Zoom platform. For an outcome to be included in the core outcome set 70% or more of participants in both groups were required to give a rating of 7-9.

**Other analyses**

Attrition bias between R1 and R2 of the online Delphi was assessed by comparing the distribution of mean R1 scores for participants completing R1 only and participants completing both R1 and R2. Satisfaction with the consensus meeting process, organisation and outcome was assessed using an online questionnaire sent to consensus meeting participants by email (supplementary file 3).

|  |
| --- |
| **Table 1. Definition of consensus** |
| **Consensus Classification** | **Description** | **Definition** |
| **Consensus in** | Consensus that outcome should be included in the core outcome set | 70% or more participants in **each** stakeholder group scoring as 7-9 AND <15% participants in each stakeholder group scoring as 1-3 |
| **Consensus out** | Consensus that outcome should not be included in the core outcomes set | 50% or fewer participants scoring 7-9 in **each** stakeholder group. |
| **No consensus** |  Uncertainty about importance of outcome | Anything else |

**Ethical approval, study registration and study oversight**

The FSR-SCOUT study was prospectively registered with the COMET Initiative (Core Outcome Measures in Effectiveness Trials) (ref 1156). Ethical approval was obtained from the University of Liverpool Research Ethics Committee prior to undertaking the consensus methods (online Delphi and consensus meeting) ref:5211. The FSR-SCOUT study is reported in line with the Core Outcome Set – Standards for Reporting (COS-STAR) reporting guidance [16]. Study oversight was provided by a Steering Committee comprised of five sarcoidosis experts and healthcare professionals, a psychometrician, a patient, two pharmaceutical representatives with sarcoidosis research experience, 2 regulatory experts with FDA experience, a representative from the Foundation for Sarcoidosis Research and three members from the COMET Initiative.

**Results**

An overview of the COS development process and final COS is shown in figure 1. The final COS includes 15 outcomes across five domains (table 2).

|  |
| --- |
| **Table 2 . Outcomes included in the Core Outcome Set** |
| **Domain**  | **Outcome** | **Outcome description**  |
| Physiological/Clinical | Disease activity | A measure of current, active, inflammation indicating active sarcoidosis. |
| Physiological/Clinical | Extra pulmonary organ involvement | Having sarcoidosis in other organs as well as the lungs |
| Physiological/Clinical | Extra pulmonary organ impairment | When sarcoidosis causes problems in other organs meaning that they don’t function properly and/or may worsen over time. |
| Physiological/Clinical | Dyspnoea | Shortness of breath/being unable to catch breath |
| Physiological/Clinical | Pulmonary function | How well someone's lungs are working |
| Physiological/Clinical | Oxygenation | How well oxygen is being sent to parts of the body |
| Physiological/Clinical | Functional exercise capacity | Includes what day to day activities someone is able to do including the ability to do complete physical activity and exercise. This includes the ability to walk (including, for example, walking up an incline, walking a long distance and walking whilst talking) |
| Quality of Life | Health related quality of life | An overall measure of how a person’s health affects their general wellbeing; perceived physical, mental and social health over time |
| Treatment | Adherence to treatment | The degree to which someone follows medical advice or guidance from their doctor, for example, taking their prescribed medications.  |
| Treatment | Tolerability of treatment | How tolerable the treatment is, for example, burden of treatment, side effects etc.  |
| Treatment | Treatment failure | When the current treatment is no longer working to control pulmonary sarcoidosis symptoms |
| Treatment | Side effects of treatment | When the treatment given causes unwanted/unintended effects  |
| Resource Use | Need for hospitalisation because of pulmonary sarcoidosis | How often someone is admitted to hospital because of pulmonary sarcoidosis |
| Death  | Death - any cause | Death from any cause |
| Death | Death - pulmonary sarcoidosis | Death as a result of having pulmonary sarcoidosis |

**Development of the long list of outcomes**

The systematic review of clinical trials and qualitative literature has been presented in detail elsewhere[12].

The review of registered clinical trials identified 36 trials, eligible for inclusion that reported a total of 364 individual outcomes, representing 56 unique outcomes. Six qualitative reports were included reporting 179 individual and 82 unique outcomes. Three patient questionnaires were completed and the verbatim free text responses identified 54 individual outcomes representing 26 unique outcomes in that data set. The taxonomy of Dodd et al [13] was applied to all outcomes. The unique outcomes were pooled from all sources and grouped by taxonomy domain, outcomes in each domain were then reviewed by the SSC. Outcomes were further grouped where appropriate, for example, outcomes relating to extra-pulmonary organ involvement such as outcomes relating to the eyes or heart were grouped into the outcome “extra pulmonary organ involvement” and the outcome “pulmonary inflammation” was grouped with “disease activity”. Outcomes considered to be related to a diagnosis rather than treatments were not included. In the interests of achieving a manageable outcomes list outcomes that were reported in a single study only were reviewed by the SSC and were not taken forward to the R1 outcomes list. The final list of outcomes (supplementary file 4) that was rated in R1 of the Delphi survey included 49 outcomes grouped under five domains (mortality n=2, life impact n = 27, physiological/clinical n=17,resource use n= 2 and adverse events n=1)[17]. The list of outcomes was randomised by domain in the online Delphi process.

**Online Delphi process**

Three hundred and ten participants completed both R1 and R2 of the online Delphi survey. Participants comprised 378 patients/carers and 53 health professionals (Table 3).

|  |
| --- |
| **Table 3. Round 2 completion rates** |
|  | **Number of participants (%)** |
| **Total number of participants invited to R2** | **433**  |
| Patients and carers invited to R2  | 378 |
| Health professionals invited to R2  | 53 |
| **Total completing R2** | **310 (71)** |
| Total patients and carers completing R2 | 259 (68) |
| Total Health Professionals | 51 (96) |

At the end of R1 13 outcomes had reached the definition of “consensus in” with 70% or more of participants in both stakeholder groups rating the outcome 7-9. One hundred and eighteen responses were received to the free text question that asked participants if there were any outcomes they thought were missing from the list and should be added. The free text relating to additional outcomes was reviewed by the SSC. Sixteen free text additional outcome responses and one feedback comment related to “extra pulmonary organ impairment” and this was included as an outcome in R2. The remaining 102 responses were excluded as they either did not represent an outcome i.e. were related to “how” an outcome should be measured (n=37), were not related to pulmonary sarcoidosis (n=6), or were already included in an existing outcome (n=59).

Feedback provided by participants was also reviewed for potential outcomes. The feedback included one comment related to relapse "at present I am in remission but worry about relapse" and the SSC agreed that this should be included as an additional outcome in R2 “Relapse: sarcoidosis coming back after a period of remission”.

At the end of R2 the definition of consensus was applied to the responses for each stakeholder group (Supplementary file 2 – consensus matrix). Fifteen outcomes met the definition for “consensus in” and are in COS. This included the 13 outcomes that had reached “consensus in” in R1 plus “death from any cause” and “extra pulmonary organ impairment” the latter of which was only rated in R2. Six outcomes met the definition of “consensus out” and were excluded from the core outcome set, the remaining outcomes had no consensus. The overall attrition rate between rounds was 28%, the rate of attrition was higher for patients (42%) compared to health professionals (4%) (Table 4).

|  |
| --- |
| **Table 4: Attrition between R1 and R2** |
| **Stakeholder** | **Number registered (% of total registrations)** | **Completed R1 n (% of registrations)** | **Number of participants invited to R2** | **Completed R2 n (% of completed R1 and invited to R2)** |
| Patients with pulmonary sarcoidosis or their carers | 479 | 391 (82) | 380 | 259 (68) |
| Healthcare professionals | 61 | 54 (89) | 53 | 51 (96) |
| Total | 540 | 445 (82) | 433\* | 310 (72) |
| \*This figure takes into account participants who could not be reached because of mail delivery failures (n=7) or who based on the comments that they provided in R1 were not eligible to take part because they did not have pulmonary sarcoidosis (n=3) |

The impact of attrition between rounds was assessed by comparing the average R1 scores of those who did not complete R2 against the distribution of scores for those completing both R1 and R2. Overall the average scores of participants completing R1 only were contained within the average scores of those completing both R1 and R2 (supplementary file 5).

**Consensus meeting**

All those who expressed an interest in attending the consensus meeting and had completed both R1 and R2 (n=39) were given further meeting information including the date of the meeting. Twenty five participants (7 health professionals, 17 patients), confirmed they were able to attend. Based on the number who responded, no restrictions were put in place on attendance. However, to try an increase the number of health professionals attending, an additional email invitation was sent to all health professionals completing R1 and R2. (Table 5).

|  |
| --- |
| **Table 5. Consensus meeting participants** |
|  | N (%) |
| **Healthcare professionals** | **7 (100%)** |
| **Role** |  |
| Sarcoidosis specialist | 3 (43%) |
| Researcher in the field | 1 (14%) |
| Industry representative | 3 (43%) |
| **Country of residence** |  |
| United States | 5 (71%) |
| India | 1 (14%) |
| The Netherlands | 1 (14% |
|  |  |
| **Patients with pulmonary sarcoidosis** | 17 (100%) |
| **Country of residence** |  |
| United States | 14 (82%) |
| UK | 3 (18%) |

Seventeen outcomes, that had not reached consensus, were prioritised for discussion at the consensus meeting as either 70% or more of participants in one stakeholder group, or 50-69% of participants in both stakeholder groups, had rated the outcome 7-9.

For the purpose of the consensus meeting the 17 outcomes, prioritised for discussion, were grouped into four domains, physiological/clinical (8 outcomes), health and quality of life (3 outcomes), life impact (5 outcomes) and treatment (1 outcome). All outcomes in a particular domain were presented, alongside those outcomes already included in the COS, and participants of the meeting invited to provide comments for inclusion of outcomes followed by comments against. After discussion of outcomes in that domain participants rated each outcome, that had been discussed, using the 1-9 scale (1 not that important – 9 critically important). Patients and health professionals voted separately, for an outcome to be included in the core outcome set 70% or more of participants in both groups were required to give a rating of 7-9. The results of consensus meeting ratings are provided in Table 6 and a full meeting report is available in supplementary file 6.

|  |
| --- |
| **Table6 . Summary of outcome discussed and rated during the consensus meeting** |
| Domain | Outcome |  | % patients rating 7-9 in online Delphi | % HCPs voting 7-9 in online Delphi | % Patients voting 7-9 in consensus meeting | % HCPs voting 7-9 in consensus meeting | Result |
| **Physiological/clinical** | Cough | Cough | 70 | 59 | 70% | 57% | Not included in the COS |
| Fatigue | An overwhelming, sustained sense of extreme tiredness or lethargy resulting in physical and/or mental weariness | 88 | 61 | 80% | 14% | Not included in the COS |
| Recurrence of sarcoidosis | Sarcoidosis coming back after a period of remission | 86 | 69 | 50% | 29% | Not included in the COS |
| Systemic inflammation | An immune response resulting in inflammation in the whole body, including the lungs | 92 | 54 | Not discussed or rated | Not discussed or rated | Not included in the COS |
| Pain | A feeling of noticeable discomfort or an unpleasant physical sensation, in general, experienced anywhere in the body. | 73 | 29 | Not discussed or rated | Not discussed or rated | Not included in the COS |
| Chest pain | Pain specifically in the chest | 78 | 27 | Not discussed or rated | Not discussed or rated | Not included in the COS |
| Mobility | Includes ability to walk, climb, run, stand, sit without difficulty, taking into account stiffness. | 78 | 45 | Not discussed or rated | Not discussed or rated | Not included in the COS |
| Infection | The presence of an unexpected and unwanted virus, bacteria, fungus or mycobacteria anywhere in the body | 79 | 26 | Not discussed or rated | Not discussed or rated | Not included in the COS |
| **Quality of life/ general health** | Overall quality of life | A state of health, happiness, comfort and well-being | 88 | 67 | 47 | 0 | Not included in the COS |
| General Health | Someone's general health | 74 | 45 | 44 | 0 | Not included in the COS |
| Perceived health status | How someone thinks their overall health is | 63 | 55 | 25 | 0 | Not included in the COS |
| **Life impact outcomes** | Activities of daily living | Being able to take care of oneself and complete usual daily activities/tasks, for example, eating, bathing and dressing oneself | 83 | 69 | 58 | 17 | Not included in the COS |
| Ability to work or study | Someone's ability to work or study, ability to gain or keep employment, influence of pulmonary sarcoidosis on the type of job or study undertaken, time off from work or study, impact on career. | 78 | 63 | 17 | 17 | Not included in the COS |
| Ability to undertake usual role/responsibilities | Being able to manage personal role and responsibilities | 75 | 49 | 33 | 17 | Not included in the COS |
| Ability to take part in usual family life/activities | Being able to take part in family life and activities | 70 | 43 | 42 | 17 | Not included in the COS |
| Cognitive Function | Mental abilities/mental processes, including memory, concentration, language and thinking. | 80 | 45 | 67 | 0 | Not included in the COS |
| **Treatment outcomes** | Satisfaction with treatment | How satisfied someone is with the treatment/s they are receiving including satisfaction with its effectiveness (how well it's working) and the time spent on treatment. | 85 | 49 | 50 | 0 | Not included in the COS |

Feedback forms from the meeting were completed by 4 (57%) health professionals and 15 (88%) patients. Overall meeting participants were satisfied with the information provided before and during the meeting, with the meeting facilitation and opportunities to contribute to the meeting, the meeting length and format, and that the meeting produced a fair result. Free text feedback included the desire for a greater number of health professional participants in the meeting and a wider geographical range of participants. The meeting was conducted using the Zoom platform and although participants overall were satisfied with the use of Zoom the free text feedback was mixed about the desire to have as short as meeting as possible whilst also having more time to allow for a longer discussion and the challenges of having a longer online meeting. One participant also commented on the challenge of following the chat discussion alongside the verbal discussion.

**Discussion**

The FSR-SCOUT study has developed a COS for pulmonary sarcoidosis with consensus from both patients and health professionals. Although the opinions of a large number of patients has contributed to the consensus process these, like the health professionals, were predominantly from the United States. The geographical location of participants is largely due to the areas covered by the patient and health professional organisations who distributed the invitations to take part. Although some of these had an international reach, particularly for health professionals, global uptake of the invitation to the Delphi survey was low. Ratification of the COS and further engagement with international patient and health professional organisations may be helpful to confirm the importance of the outcomes to stakeholders with differing cultures and experiences of healthcare.

Previous work to identify important outcomes for pulmonary sarcoidosis research has involved a single stakeholder group and in one case considered only a small specific set of outcomes. Nevertheless there is overlap in the outcomes in the current COS with the majority of outcomes recommended by Baughman et al and Kampstra et al[18, 9, 8] (supplementary file 7). The exception being “imaging” and imaging components of “clinical outcome status” (chest X-ray scanning and High-resolution computed tomography (HRCT) score[18]). In the current study these outcomes were grouped and rated in the Delphi survey as “radiographic outcomes” but, after R2, this outcome did not meet the criteria for “consensus in” in either of the stakeholder groups. Judson et al have also proposed overarching endpoints for trials of treatment for acute pulmonary sarcoidosis, chronically treated pulmonary sarcoidosis and fibrotic pulmonary sarcoidosis. These include improvement/resolution of granulomatous inflammation, improvement/worsening in pulmonary physiology/function, improvement/worsening in function status or QOL or both, and reduction in side effects of treatment which are included within the outcomes within the proposed COS.

Despite the large overlap in outcomes identified by the different initiatives, the inclusion of both patients and health professionals in the current study has identified additional, critically important, outcomes relating to treatment, disease progression and symptoms that have not previously been prioritised, highlighting the importance of integrating stakeholder opinions in the development of the COS.

The study included a consensus meeting to discuss outcomes that had not reached consensus during the Delphi process. An opportunistic sample of participants expressing an interest in attending formed the basis of the consensus meeting and resulted in twenty-four consensus meeting participants of which only seven were health professionals. This small number of health professionals may mean that a smaller range of views and experiences were represented. However, the average R2 scores of health professionals attending the consensus meeting were similar to the group average for all outcomes (5.8 and 6.5 respectively) and also similar for individual outcomes of cough (6.6 consensus meeting participants and 6.6 all participants) and fatigue (5.4 consensus meeting participants and 6.1 all participants). This was also true for patients (supplementary file 6).

Consensus has been reached on the inclusion of 15 outcomes, yet there were a number of other outcomes, that met the definition of “no consensus” and that patients rated as “consensus in” and health professionals did not These outcomes were discussed and voted on at the consensus meeting. Two of the outcomes, “fatigue” and “cough” continued to meet the definition of no consensus (table 1). Both fatigue and cough are frequently reported symptoms of pulmonary sarcoidosis. In the literature, exploring patient experiences of sarcoidosis, fatigue was reported by 90% of respondents [19] and in one study it was reported as the most disabling symptom by 40% of sarcoidosis patients [20]. Likewise cough is often frequently reported and may affect up to 53% of patients [21, 22] and both fatigue and cough have been reported to impact on the quality of life of patients with sarcoidosis [23, 24] . Existing pulmonary specific HRQL measures such as the St George’s Respiratory Questionnaire, Sarcoidosis Health Questionnaire[25] and the Kings Sarcoidosis Questionnaire [26] include some items relating to cough, and tiredness/fatigue. Consensus is now needed on how each of the outcomes in the core outcome set should be measured and we recommend that the outcomes “fatigue” and “cough” be taken into consideration when agreeing how to measure health related quality of life.

**Conclusions**

The COS developed in the FSR-SCOUT study has identified outcomes considered to be the most important, and critical to measure in future research for pulmonary sarcoidosis, by both patients and health professionals. The uptake of the COS will increase the relevance of research outcomes to key stakeholders and the potential for comparisons to take place across trials, thereby reducing waste in research.

**Figure 1 – Overview of the development of the Core Outcome Set**

**Delphi Round 1**

**433 responses**

391 Patients and carers

54 Healthcare professionals & researchers

**15 outcomes** included in the final core outcome set

*Table 2.*

Analysis of free text responses to additional outcomes question.

Two outcomes added.

**51 outcomes taken forward to round 2**

**Consensus meeting**

**25 voting participants**

7 healthcare professionals & researchers

17 patients

Online Delphi Survey

Consensus meeting

**51 outcomes scored**

Fifteen outcomes met the definition of consensus “In” across both stakeholder groups. *(supplementary file 2)*

**Delphi Round 2**

**310 responses**

259 Patients and carers

51 Health professionals & researchers

**49 outcomes scored**

Thirteen outcomes met the definition of consensus “in” across both stakeholder groups.

Development of long list of outcomes

Outcomes term categorisation, domain grouping and review by SSC

**49 outcomes**

Outcome extraction

Clinical trials.gov studies

364 individual outcomes (56 unique outcomes)

Rapid qualitative review

179 individual outcomes (82 unique outcomes)

Patient questionnaire

54 individual outcomes (26 unique outcomes)

Patient questionnaire

(n=3)

Systematic review of clinicaltrials.gov entries

128 records screened

36 entries included

Rapid review of qualitative studies

238 studies screened

6 studies included

**Funding**

This study was funded by the Foundation for Sarcoidosis Research (<https://www.stopsarcoidosis.org/>). The Funder was an active member of the Study Management Group; they facilitated organization of meetings with the Study Steering Committee, contributed to the study design and reviewed the manuscript.

**Conflicts of Interest**

### NLH, SLG, PRW, RPB, MAJ, NAK, DEV, JCG, DAC have no competing interests

### ESBis an employee of Janssen Research and Development, LLC, who has sponsored research studies in Sarcoidosis

### EJS is an employee of Insmed Incorporated

### MW employee of Janssen Research & Development

### HJ is a sarcoidosis patient

### TA-H, HN and NS were employed by the funder (The Foundation for Sarcoidosis Research) during the research.

### Acknowledgements

### We thank all Delphi participants for their contributions to the study and have detailed those who wished to be acknowledged by name.

### Adam Anderson, Adam S. Morgenthau, Adriane DM Vorselaars, Aidan Marsden, Alan Bart Cameron MD Sr, Amanda Anderson, Andrew Berman, Angela Bjerke, Angela Kattenbraker, Anita Edwards, Anna Dubaniewicz, Barbara Madigan, Barry Edginton, Bernd Quadder, Bobbie Molony, Bonnie Rock, Bonnie Stoner, Brea George, Brian Anders, Brian Stein, Carita Wegner, Carlton Hall, Carol L Larson, Cathy Bauer, Charles M Holmes, Charles Roark, Charlotte Demory, Cheryl Crick, Chet Zaffarano, Chris MacDonald, Christine Beck, Christine Hostetter, Cliona Barrett, Conrad A Wilmot, Craig Conoscenti; MD; FCCP; ATSF, Cynthia L. Goss, Dana Himes, Dana Papworth, Danette Griffith, David Bailey, David C. Summa, David Erikson, David Moller, David White, Deanna Sturgeon, Debabrata Bandyopadhyay, Debbie Gordon, Deborah Eubank, Delph Gustitus, Denise B, Diane Wilkins, Dianne Hilton, Dianne Hilton, Divya Patel, Donald Bowman, Donna Robinson, Ed Cadwell, Ed Whetter, Ellen Papper, Elliott Crouser; MD, Emily Stott, Ennis James, Eugene Sullivan, Evelyn Jayne Williams, Frank Rivera, Gary Jackson, Gary Moline,George Clos, Hal Shear, Heather Kamper, Heidi Junk, Ian Danks, Ilias Papanikolaou, Irina Strambu, James G Kuhn, James Goodloe, Janice Desimone, Janne MÃ¸ller, JC Grutters, Jennifer Dean, Jim Mitchell, Joachim Dekkers, Joan Corcoran, Johanna J Hyman, John Berry, John D. Gwinn, John Kilcoyne, John Mangus, Joseph A Franco, Josephine Rowe, Josh Moll, Joy G McCulley, Juan Carlos Quijano-Campos, Juanita Phillips, Julie Buter, Julie Rigg, Karen Green, Karin Jurgersen, Kathy, Kelly Franklin, Kenneth Shields, Kevin Mercer, Kim Fletcher, Kristen Arns, Larry Rosenstiel, Lesley Cochrane, Lexie Peters, Lina Britton, Linda Mosiello, Lisa Cooper Colvin, Lisa Hodgson, Lisa Westby, Lori Andrews, Lou Fogg, Louis, Lyle Raustadt, Lynn Magill, M. Voortman, Joachim Mueller-Quernheim, Madeline Roth, Malcolm O'Condell, Marc Walton, Marcel Veltkamp, Marcie Dimenstein, Marcy Medley, Marios Rossides, Mark Ashton, Mark Brodner, Mark Bustard, Mark Massmann, Mark Zanfardino, Marlies Wijsenbeek, Marquita Jones, Michael Boris, Michael Heffner, Murray Baron, Nabeel Hamzeh, Nancy Groceman, Niall Fitzgerald, Nichole Carlson,Nina Elaine Jett, Nurys Montepeque, Ogugua Ndili Obi; MD; MPH; MSc, Patricia Clark, Paul Paradis, Paul Thomas, Peter Smith, Peter Sporn, Philip Doherty jr, Philippa Mckeown ,Prof. Marjolein Drent, Rafael Perez, Ralph Tomaccio, Ray McJunkin, Raymond Brooks, Rebecca Lucciani, Regina Gordon, Revital Horowitz, Richard Stefanowski, Rick Paul, Robert Baughman, Robert Felderman, Robert Gross, Robert P Jones, Roberta S. Levin, Roberta S. Levin, Roger Ross, Rohit Gupta, Rosalind Ruoti, Roy Carter, Sahajal Dhooria, Sandra A. Avalos, Sarah Keast, Shelley Kleinsasser, Sherri Steel, Sheryl Fruithandler, Shu-Yi Liao, Simon Hart, Srihari Veeraraghavan, Stefan Rustscheff, Stephanie Paul, Stephanie Ryan, Stephen Savies, Steve Cowan, Steve Meredith, Sue Kenworthy, Susan Bassi, Susan Long, Tamera McKibben, Telicia Perry, Theresa Fisher, Tiago Alfaro, Tom Torp, Tonya K Sephus, Tyler, Udo Luebben, Vincent Artymko, Ward Ricke, Wayne Randall, Wim Wuyts, Wonder Drake.

### References

1. Costabel U, Hunninghake G. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. European Respiratory Journal. 1999;14(4):735-7.

2. James WE, Koutroumpakis E, Saha B, Nathani A, Saavedra L, Yucel RM et al. Clinical Features of Extrapulmonary Sarcoidosis Without Lung Involvement. Chest. 2018;154(2):349-56. doi:https://doi.org/10.1016/j.chest.2018.02.003.

3. Culver DA, Judson MA. New advances in the management of pulmonary sarcoidosis. BMJ. 2019;367:l5553. doi:10.1136/bmj.l5553.

4. Harman NL, Gorst SL, Williamson PR, Barnathan ES, Baughman RP, Judson MA et al. Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG. 2021;38(3):e2021034-e. doi:10.36141/svdld.v38i3.10737.

5. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. The Cochrane database of systematic reviews. 2005;2005(2):Cd001114. doi:10.1002/14651858.CD001114.pub2.

6. Paramothayan S, Lasserson TJ, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. The Cochrane database of systematic reviews. 2006(3):Cd003536. doi:10.1002/14651858.CD003536.pub2.

7. Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST et al. The COMET Handbook: version 1.0. Trials. 2017;18(3):280. doi:10.1186/s13063-017-1978-4.

8. Baughman RP, Barriuso R, Beyer K, Boyd J, Hochreiter J, Knoet C et al. Sarcoidosis: patient treatment priorities. ERJ Open Res. 2018;4(4):00141-2018. doi:10.1183/23120541.00141-2018.

9. Kampstra NA, Grutters JC, van Beek FT, Culver DA, Baughman RP, Renzoni EA et al. First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative. BMJ Open Respiratory Research. 2019;6(1):e000394. doi:10.1136/bmjresp-2018-000394.

10. Kirkham JJ, Davis K, Altman DG, Blazeby JM, Clarke M, Tunis S et al. Core Outcome Set-STAndards for Development: The COS-STAD recommendations. PLOS Medicine. 2017;14(11):e1002447. doi:10.1371/journal.pmed.1002447.

11. Gorst SL HNJM, Grutters J , Barnathan E, Baughman R, Culver D, Junk H, Kampstra N, Singh N, Sullivan E, Victorson D, Walton MK, Williamson PR. SCOUT: Sarcoidosis Clinical OUTcomes task force: protocol for the development of a core outcome set in pulmonary sarcoidosis. 2020. https://[www.stopsarcoidosis.org/wp-content/uploads/SCOUT-Protocol-V2.0-4-5-20202.pdf](http://www.stopsarcoidosis.org/wp-content/uploads/SCOUT-Protocol-V2.0-4-5-20202.pdf). Accessed 19-11-2020.

12. Harman NL, Gorst SL, Williamson PR, Elliot S. Barnathan, Baughman RP, Judson MA et al. SCOUT – Sarcoidosis Outcomes Taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Disease. 2021;In Production

13. Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. Journal of clinical epidemiology. 2018;96:84-92. doi:10.1016/j.jclinepi.2017.12.020.

14. Initative C. <http://www.comet-initiative.org/delphimanager/>. Accessed 10-11 2020.

15. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of clinical epidemiology. 2011;64(4):395-400. doi:10.1016/j.jclinepi.2010.09.012.

16. Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D et al. Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. PLoS medicine. 2016;13(10):e1002148-e. doi:10.1371/journal.pmed.1002148.

17. Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. Journal of Clinical Epidemiology. 2018;96:84-92. doi:https://doi.org/10.1016/j.jclinepi.2017.12.020.

18. Baughman RP, Nagai S, Balter M, Costabel U, Drent M, du Bois R et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG. 2011;28(1):56-64.

19. Voortman M, Hendriks CMR, Elfferich MDP, Bonella F, Møller J, De Vries J et al. The Burden of Sarcoidosis Symptoms from a Patient Perspective. Lung. 2019;197(2):155-61. doi:10.1007/s00408-019-00206-7.

20. Moor CC, van Manen MJG, van Hagen PM, Miedema JR, van den Toorn LM, Gür-Demirel Y et al. Needs, Perceptions and Education in Sarcoidosis: A Live Interactive Survey of Patients and Partners. Lung. 2018;196(5):569-75. doi:10.1007/s00408-018-0144-4.

21. Harrison NK. Cough, sarcoidosis and idiopathic pulmonary fibrosis: raw nerves and bad vibrations. Cough. 2013;9(1):9-. doi:10.1186/1745-9974-9-9.

22. Pietinalho A, Ohmichi M, Hiraga Y, Löfroos AB, Selroos O. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG. 1996;13(2):159-66. doi:10.1007/bf00389839.

23. Michielsen HJ, Peros-Golubicic T, Drent M, De Vries J. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration; international review of thoracic diseases. 2007;74(4):401-5. doi:10.1159/000092670.

24. Brignall K, Jayaraman B, Birring SS. Quality of life and psychosocial aspects of cough. Lung. 2008;186 Suppl 1:S55-8. doi:10.1007/s00408-007-9034-x.

25. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The Sarcoidosis Health Questionnaire. American Journal of Respiratory and Critical Care Medicine. 2003;168(3):323-9. doi:10.1164/rccm.200211-1343OC.

26. Patel AS, Siegert RJ, Creamer D, Larkin G, Maher TM, Renzoni EA et al. The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax. 2013;68(1):57-65. doi:10.1136/thoraxjnl-2012-201962.